- Potential offer values the company at 4,070p per share, a 34 per cent premium
- Interim results showed growth but R&D spending hit earnings
Dechra Pharmaceuticals (DPH) shareholders are set for a treat, after the veterinary products company said it would recommend a 4,070p per share cash buyout by Swedish private equity for EQT. This puts a £4.6bn valuation on the company, a 52 per cent premium on its price before a blog published details of the deal on Thursday afternoon. Its shares climbed to 3,752p on the news, although this is still below its 12-month high of 4,130p.